Cyclin-dependent kinase inhibitor 2C (CDKN2C)

Cyclin-dependent kinase inhibitor 2C (CDKN2C), commonly known as p18-INK4C, is a member of the INK4 family of CDK inhibitors that regulates cell cycle progression by inhibiting the activation of cyclin-dependent kinases 4 and 6 (CDK4/6)[1][2][4][6]. By blocking these kinases, CDKN2C acts as a key negative regulator of the G1 phase, functioning as a tumor suppressor and preventing uncontrolled cell proliferation. It is implicated in various physiological processes such as spermatogenesis and is frequently studied in the context of tumorigenesis where its loss or mutation is associated with several cancers[1][2][4]. CDKN2C is considered a potential biomarker and a target for modulation by small molecule CDK4/6 inhibitors in oncology[3][4].

Other names

p18INK4Cp18-INK4Cp18-INK6CDKN6Cyclin-dependent kinase 4 inhibitor Cp18-INK4cCyclin-dependent kinase 6 inhibitorCDK6 inhibitor p18

Inhibition of cyclin-dependent kinases CDK4 and CDK6 by blocking their activation, resulting in cell cycle arrest at G1 phase[1][2][3][4]